Shire PLC; market cap: $28.38bn (as of 06/11/2015) Dyax Corporation; market cap: $5.1bn (as of 06/11/2015) Introduction On November 2, Dublin-headquartered pharmaceutical company Shire Plc agreed to acquire the Massachusetts-based biopharma company Dyax Corporation for an upfront cash consideration of $5.9bn and an additional $646m payment contingent on the Read more…
AbbVie Inc.; market cap (as of 06/03/2015): $88.7bn Pharmacyclics Inc.; market cap (as of 06/03/2015): $19.3bn Introduction On March 4, the pharmaceutical company AbbVie, outbidding the competitor Johnson & Johnson, agreed to buy the cancer biotech company Pharmacyclics in a $21bn transaction. The Chicago based company will pay $261.25 per Read more…
AbbVie Inc., Market Cap (as of 19/09/2014): $94.63bn Shire plc., Market Cap (as of 19/09/2014): £31.12bn In its attempt to become one of the global leaders in the rare diseases market, AbbVie successfully got the approval from Shire’s board of directors for its $54bn acquisition. This approval came after two Read more…
Shire PLC Market Cap (as of 15/11/13): £15.7bn ViroPharma Inc. Market Cap (as of 15/11/13): $3.3bn Monday, November 11th brought about the much rumored king-size deal of the year in the pharmaceutical sector: Shire PLC of Ireland acquired ViroPharma Inc., a US-based niche company focused on rare diseases, for a Read more…